HER2 Proven Diagnostic Accuracy

HER2 treatment targets both patients with breast and gastric cancer indications.

Since 1998, laboratories around the world have relied on the diagnostic accuracy of Dako HER2 testing for breast cancer. Herceptin® therapy has now become a standard of care for HER2-overexpressing metastatic breast cancer, and a pharmDx™ test for HER2 protein overexpression or HER2 gene amplification is conducted to assess Herceptin® eligibility.

In addition a recent clinical study shows that HercepTest™ and HER2 FISH pharmDx™ Kit accurately identify patients with gastric cancer who may benefit from trastuzumab treatment (Lancet 2010; 376:687-07).

Dako has also received approval from the U.S. FDA to expand the use of the HercepTest™ and HER2 pharmDx™ Kits to include patients with metastatic gastric or gastricesophageal junction adenocarcinoma (Lancet 2010; 376:687-07).

Leading pathologists endorse and use HercepTest™: See and hear why!

Country selection

Your Dako Account indicates that you are based in , you will be transfered to the web site for

Basket emptied

Your basket was emptied because of the country change.

Country selection

United States of America appears to be your location. To view country specific information on the Dako web site, please accept or change country below.

Dako Cookie Policy
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Privacy Statement

Get in Touch with Dako in Luxemburg

Contact Us Directly

+32 16/93.00.30
+32 16/93.00.31

Pathology Products, Flow Cytometry Products and Specific Proteins
Please inquire at
Dako Belgium BVA/SPRL

Technologielaan 3
B-3001 Heverlee

Detailed contact information

Submit an Inquiry

How would you like us to follow up?

Your session expired

You have been logged out. Log in again to retrieve your Cart.